The effects of cyclooxygenase-2 gene silencing by siRNA on cell proliferation, cell apoptosis, cell cycle and tumorigenicity of Capan-2 human pancreatic cancer cells

Eschwège P, de Ledinghen V, Camilli T, et al: Arachidonic acid and prostaglandins, inflammation and oncology. Presse Med. 30:508–510. 2001.(In French).

Zhong YQ, Shen XM, Li HG, et al: Expression of hTERT and its correlation with expression of P-gp, COX-2, Bcl-2 and the clinical pathological features of patients with pancreatic cancer. Zhonghua Linchuang Yishi Zazhi. 2:14–18. 2008.

Zhong YQ, Xia ZS, Fu YR, et al: Knockdown of hTERT by siRNA suppresses growth of Capan-2 human pancreatic cancer cell via the inhibition of expressions of Bcl-2 and COX-2. J Dig Dis. 11:176–184. 2010. View Article : Google Scholar : PubMed/NCBI

Zhong YQ, Huang HR, Fu YR, et al: Effect of silencing expression of hTERT gene by siRNA on the expression of Bcl-2 and COX-2 genes of human pancreatic cancer cells in vitro. Zhonghua Linchuang Yishi Zazhi. 4:34–38. 2010.

Pai R, Soreghan B, Szabo IL, et al: Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 8:289–293. 2002. View Article : Google Scholar : PubMed/NCBI

Fujino H, West KA and Regan JW: Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J Biol Chem. 277:2614–2619. 2002. View Article : Google Scholar : PubMed/NCBI

Liu XH, Kirschenbaum A, Lu M, et al: Prostaglandin E (2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway. Biochem Biophys Res Commun. 290:249–255. 2002. View Article : Google Scholar : PubMed/NCBI

Eibl G, Bruemmer D, Okada Y, et al: PGE (2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun. 306:887–897. 2003. View Article : Google Scholar : PubMed/NCBI

Ito H, Duxbury M, Benoit E, et al: Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res. 64:7439–7446. 2004. View Article : Google Scholar : PubMed/NCBI

Juuti A, Louhimo J, Nordling S, et al: Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol. 59:382–386. 2006. View Article : Google Scholar : PubMed/NCBI

Xu L, Li YM, Yu CH, et al: Expression of p53, p16 and COX-2 in pancreatic cancer with tissue microarray. Hepatobiliary Pancreat Dis Int. 5:138–142. 2006.PubMed/NCBI

Tucker ON, Dannenberg AJ, Yang EK, et al: Cyclooxygenase-2 expression is upregulated in human pancreatic cancer. Cancer Res. 59:987–990. 1999.PubMed/NCBI

Ding XZ, Tong WG and Adrian TE: Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res. 20:2625–2631. 2000.PubMed/NCBI

Yao M, Zhou W, Sangha S, et al: Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res. 11:1618–1628. 2005. View Article : Google Scholar : PubMed/NCBI

Shaik MS, Chatterjee A and Singh M: Effect of a selective Cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma. Clin Cancer Res. 10:1521–1529. 2004. View Article : Google Scholar

Chen G and Duan HJ: Therapeutic effect of different doses of celecoxib on human lung cancer xenograft in nude mice and its action mechanism. Tumor. 28:837–841. 2008.

Bresalier RS, Sandler RS, Quan H, et al: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 352:1092–1102. 2005. View Article : Google Scholar : PubMed/NCBI